Short Interest in Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) Grows By 1,500.0%

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY - Get Free Report) was the target of a significant growth in short interest in January. As of January 15th, there was short interest totalling 36,800 shares, a growth of 1,500.0% from the December 31st total of 2,300 shares. Based on an average daily trading volume, of 214,500 shares, the days-to-cover ratio is currently 0.2 days.

Chugai Pharmaceutical Price Performance

Shares of OTCMKTS CHGCY traded up $2.03 during mid-day trading on Friday, hitting $22.36. The company had a trading volume of 164,036 shares, compared to its average volume of 213,020. Chugai Pharmaceutical has a 1-year low of $14.52 and a 1-year high of $26.00. The company has a market capitalization of $73.59 billion, a PE ratio of 28.67 and a beta of 0.81. The business's 50-day simple moving average is $21.65 and its 200 day simple moving average is $22.43.

Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) last posted its earnings results on Thursday, January 30th. The company reported $0.18 EPS for the quarter. Chugai Pharmaceutical had a return on equity of 22.30% and a net margin of 33.85%. On average, analysts expect that Chugai Pharmaceutical will post 0.78 EPS for the current year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.